Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Radiation Therapy and Pembrolizumab in Patients With Localized Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy

NCT03419130 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT03419130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03419130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Radiation Therapy and Pembrolizumab in Patients With Localized Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Withdrawn
Start date
July 18, 2018
Completion date
December 31, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infiltrating bladder urothelial carcinoma, stage ii bladder urothelial carcinoma ajcc v6 and v7, stage iii bladder urothelial carcinoma ajcc v6 and v7